CD274 and non-small cell lung carcinoma: In the KEYNOTE-024 trial (20), a global phase 3 trial, patients with previously-untreated, advanced NSCLC with high PD-L1 expression (≥50%) experienced longer PFS and OS after pembrolizumab monotherapy compared to those with platinum-based chemotherapy.